Eos Biosciences, a Century City nanomedicines company affiliated with Cedars-Sinai Medical Center, has obtained a patent for a drug delivery platform aimed toward breast cancer, officials announced Tuesday.
The private Century City biotech company said it had obtained a second patent for its Eos-001 nanoparticle drug delivery system, which delivers drugs to cancer cells at the molecular level.
The latest patent, for the propriety technology known as Eosomes is targeted toward stubborn breast cancers resistant to other therapies.
“This is a very exciting time for Eos Biosciences,” Omar Haffar, Eos Bioscience’s president, chief executive and co-founder, said in a statement. “In addition to expanding and solidifying our patent portfolio, we are making very significant progress on the pre-clinical development and scale-up manufacturing of our products.”
Eos, which employs five people, was co-founded four years ago by Dr. Lali Medina-Kauwe, a professor of bioscience at Cedars-Sinai Medical Center, where it leases a lab. Eos has an exclusive license for the nanoparticle delivery system from Cedars-Sinai.
Eos Bioscience, which has obtained $4.3 million in seed and A-round funding, aims to begin clinical trials of their nano delivery system within two years.
Health business reporter Dana Bartholomew can be reached at firstname.lastname@example.org. Follow him on Twitter @_DanaBart.
This story has been updated to correct an error.